L-DOPA disrupts adenosine A2A-cannabinoid CB1-dopamine D2 receptor heteromer cross-talk in the striatum of hemiparkinsonian rats: Biochemical and behavioral studies

Annalisa Pinna, Jordi Bonaventura, Daniel Farré, Marta Sánchez, Nicola Simola, Josefa Mallol, Carme Lluís, Giulia Costa, Younis Baqi, Christa E. Müller, Antoni Cortés, Peter McCormick, Enric I. Canela, Eva Martínez-Pinilla, José L. Lanciego, Vicent Casadó, Marie Therese Armentero, Rafael Franco

Research output: Contribution to journalArticle

54 Citations (Scopus)

Abstract

Long-term therapy with l-3,4-dihydroxyphenylalanine (l-DOPA), still the most effective treatment in Parkinson's disease (PD), is associated with severe motor complications such as dyskinesia. Experimental and clinical data have indicated that adenosine A2A receptor antagonists can provide symptomatic improvement by potentiating l-DOPA efficacy and minimizing its side effects. It is known that the G-protein-coupled adenosine A2A, cannabinoid CB1 and dopamine D2 receptors may interact and form functional A2A-CB1-D2 receptor heteromers in co-transfected cells as well as in rat striatum. These data suggest that treatment with a combination of drugs or a single compound selectively acting on A2A-CB1-D2 heteromers may represent an alternative therapeutic treatment of PD. We investigated the expression of A2A-CB1-D2 receptor heteromers in the striatum of both naïve and hemiparkinsonian rats (HPD-rats) bearing a unilateral 6-hydroxydopamine (6-OHDA) lesion, and assessed how receptor heteromer expression and biochemical properties were affected by l-DOPA treatment. Radioligand binding data showed that A2A-CB1-D2 receptor heteromers are present in the striatum of both naïve and HPD-rats. However, behavioral results indicated that the combined administration of A2A (MSX-3 or SCH58261) and CB1 (rimonabant) receptor antagonists, in the presence of l-DOPA does not produce a response different from administration of the A2A receptor antagonist alone. These behavioral results prompted identification of heteromers in l-DOPA-treated animals. Interestingly, the radioligand binding results in samples from lesioned animals suggest that the heteromer is lost following acute or chronic treatment with l-DOPA.

Original languageEnglish
Pages (from-to)180-191
Number of pages12
JournalExperimental Neurology
Volume253
DOIs
Publication statusPublished - Mar 2014

Fingerprint

Receptor Cross-Talk
Dihydroxyphenylalanine
Dopamine D2 Receptors
Cannabinoids
Adenosine
Cannabinoid Receptor CB1
rimonabant
Oxidopamine
Parkinson Disease
Adenosine A2 Receptor Antagonists
Dyskinesias
Drug Combinations
GTP-Binding Proteins
Therapeutics

Keywords

  • A antagonists
  • Behavior
  • CB antagonists
  • G-protein-coupled receptors
  • L-DOPA
  • Parkinson's disease
  • Radioligand binding

ASJC Scopus subject areas

  • Neurology
  • Developmental Neuroscience

Cite this

L-DOPA disrupts adenosine A2A-cannabinoid CB1-dopamine D2 receptor heteromer cross-talk in the striatum of hemiparkinsonian rats : Biochemical and behavioral studies. / Pinna, Annalisa; Bonaventura, Jordi; Farré, Daniel; Sánchez, Marta; Simola, Nicola; Mallol, Josefa; Lluís, Carme; Costa, Giulia; Baqi, Younis; Müller, Christa E.; Cortés, Antoni; McCormick, Peter; Canela, Enric I.; Martínez-Pinilla, Eva; Lanciego, José L.; Casadó, Vicent; Armentero, Marie Therese; Franco, Rafael.

In: Experimental Neurology, Vol. 253, 03.2014, p. 180-191.

Research output: Contribution to journalArticle

Pinna, A, Bonaventura, J, Farré, D, Sánchez, M, Simola, N, Mallol, J, Lluís, C, Costa, G, Baqi, Y, Müller, CE, Cortés, A, McCormick, P, Canela, EI, Martínez-Pinilla, E, Lanciego, JL, Casadó, V, Armentero, MT & Franco, R 2014, 'L-DOPA disrupts adenosine A2A-cannabinoid CB1-dopamine D2 receptor heteromer cross-talk in the striatum of hemiparkinsonian rats: Biochemical and behavioral studies', Experimental Neurology, vol. 253, pp. 180-191. https://doi.org/10.1016/j.expneurol.2013.12.021
Pinna, Annalisa ; Bonaventura, Jordi ; Farré, Daniel ; Sánchez, Marta ; Simola, Nicola ; Mallol, Josefa ; Lluís, Carme ; Costa, Giulia ; Baqi, Younis ; Müller, Christa E. ; Cortés, Antoni ; McCormick, Peter ; Canela, Enric I. ; Martínez-Pinilla, Eva ; Lanciego, José L. ; Casadó, Vicent ; Armentero, Marie Therese ; Franco, Rafael. / L-DOPA disrupts adenosine A2A-cannabinoid CB1-dopamine D2 receptor heteromer cross-talk in the striatum of hemiparkinsonian rats : Biochemical and behavioral studies. In: Experimental Neurology. 2014 ; Vol. 253. pp. 180-191.
@article{51d43315b3c34555b34d18b6cc8d7e81,
title = "L-DOPA disrupts adenosine A2A-cannabinoid CB1-dopamine D2 receptor heteromer cross-talk in the striatum of hemiparkinsonian rats: Biochemical and behavioral studies",
abstract = "Long-term therapy with l-3,4-dihydroxyphenylalanine (l-DOPA), still the most effective treatment in Parkinson's disease (PD), is associated with severe motor complications such as dyskinesia. Experimental and clinical data have indicated that adenosine A2A receptor antagonists can provide symptomatic improvement by potentiating l-DOPA efficacy and minimizing its side effects. It is known that the G-protein-coupled adenosine A2A, cannabinoid CB1 and dopamine D2 receptors may interact and form functional A2A-CB1-D2 receptor heteromers in co-transfected cells as well as in rat striatum. These data suggest that treatment with a combination of drugs or a single compound selectively acting on A2A-CB1-D2 heteromers may represent an alternative therapeutic treatment of PD. We investigated the expression of A2A-CB1-D2 receptor heteromers in the striatum of both na{\"i}ve and hemiparkinsonian rats (HPD-rats) bearing a unilateral 6-hydroxydopamine (6-OHDA) lesion, and assessed how receptor heteromer expression and biochemical properties were affected by l-DOPA treatment. Radioligand binding data showed that A2A-CB1-D2 receptor heteromers are present in the striatum of both na{\"i}ve and HPD-rats. However, behavioral results indicated that the combined administration of A2A (MSX-3 or SCH58261) and CB1 (rimonabant) receptor antagonists, in the presence of l-DOPA does not produce a response different from administration of the A2A receptor antagonist alone. These behavioral results prompted identification of heteromers in l-DOPA-treated animals. Interestingly, the radioligand binding results in samples from lesioned animals suggest that the heteromer is lost following acute or chronic treatment with l-DOPA.",
keywords = "A antagonists, Behavior, CB antagonists, G-protein-coupled receptors, L-DOPA, Parkinson's disease, Radioligand binding",
author = "Annalisa Pinna and Jordi Bonaventura and Daniel Farr{\'e} and Marta S{\'a}nchez and Nicola Simola and Josefa Mallol and Carme Llu{\'i}s and Giulia Costa and Younis Baqi and M{\"u}ller, {Christa E.} and Antoni Cort{\'e}s and Peter McCormick and Canela, {Enric I.} and Eva Mart{\'i}nez-Pinilla and Lanciego, {Jos{\'e} L.} and Vicent Casad{\'o} and Armentero, {Marie Therese} and Rafael Franco",
year = "2014",
month = "3",
doi = "10.1016/j.expneurol.2013.12.021",
language = "English",
volume = "253",
pages = "180--191",
journal = "Experimental Neurology",
issn = "0014-4886",
publisher = "Academic Press Inc.",

}

TY - JOUR

T1 - L-DOPA disrupts adenosine A2A-cannabinoid CB1-dopamine D2 receptor heteromer cross-talk in the striatum of hemiparkinsonian rats

T2 - Biochemical and behavioral studies

AU - Pinna, Annalisa

AU - Bonaventura, Jordi

AU - Farré, Daniel

AU - Sánchez, Marta

AU - Simola, Nicola

AU - Mallol, Josefa

AU - Lluís, Carme

AU - Costa, Giulia

AU - Baqi, Younis

AU - Müller, Christa E.

AU - Cortés, Antoni

AU - McCormick, Peter

AU - Canela, Enric I.

AU - Martínez-Pinilla, Eva

AU - Lanciego, José L.

AU - Casadó, Vicent

AU - Armentero, Marie Therese

AU - Franco, Rafael

PY - 2014/3

Y1 - 2014/3

N2 - Long-term therapy with l-3,4-dihydroxyphenylalanine (l-DOPA), still the most effective treatment in Parkinson's disease (PD), is associated with severe motor complications such as dyskinesia. Experimental and clinical data have indicated that adenosine A2A receptor antagonists can provide symptomatic improvement by potentiating l-DOPA efficacy and minimizing its side effects. It is known that the G-protein-coupled adenosine A2A, cannabinoid CB1 and dopamine D2 receptors may interact and form functional A2A-CB1-D2 receptor heteromers in co-transfected cells as well as in rat striatum. These data suggest that treatment with a combination of drugs or a single compound selectively acting on A2A-CB1-D2 heteromers may represent an alternative therapeutic treatment of PD. We investigated the expression of A2A-CB1-D2 receptor heteromers in the striatum of both naïve and hemiparkinsonian rats (HPD-rats) bearing a unilateral 6-hydroxydopamine (6-OHDA) lesion, and assessed how receptor heteromer expression and biochemical properties were affected by l-DOPA treatment. Radioligand binding data showed that A2A-CB1-D2 receptor heteromers are present in the striatum of both naïve and HPD-rats. However, behavioral results indicated that the combined administration of A2A (MSX-3 or SCH58261) and CB1 (rimonabant) receptor antagonists, in the presence of l-DOPA does not produce a response different from administration of the A2A receptor antagonist alone. These behavioral results prompted identification of heteromers in l-DOPA-treated animals. Interestingly, the radioligand binding results in samples from lesioned animals suggest that the heteromer is lost following acute or chronic treatment with l-DOPA.

AB - Long-term therapy with l-3,4-dihydroxyphenylalanine (l-DOPA), still the most effective treatment in Parkinson's disease (PD), is associated with severe motor complications such as dyskinesia. Experimental and clinical data have indicated that adenosine A2A receptor antagonists can provide symptomatic improvement by potentiating l-DOPA efficacy and minimizing its side effects. It is known that the G-protein-coupled adenosine A2A, cannabinoid CB1 and dopamine D2 receptors may interact and form functional A2A-CB1-D2 receptor heteromers in co-transfected cells as well as in rat striatum. These data suggest that treatment with a combination of drugs or a single compound selectively acting on A2A-CB1-D2 heteromers may represent an alternative therapeutic treatment of PD. We investigated the expression of A2A-CB1-D2 receptor heteromers in the striatum of both naïve and hemiparkinsonian rats (HPD-rats) bearing a unilateral 6-hydroxydopamine (6-OHDA) lesion, and assessed how receptor heteromer expression and biochemical properties were affected by l-DOPA treatment. Radioligand binding data showed that A2A-CB1-D2 receptor heteromers are present in the striatum of both naïve and HPD-rats. However, behavioral results indicated that the combined administration of A2A (MSX-3 or SCH58261) and CB1 (rimonabant) receptor antagonists, in the presence of l-DOPA does not produce a response different from administration of the A2A receptor antagonist alone. These behavioral results prompted identification of heteromers in l-DOPA-treated animals. Interestingly, the radioligand binding results in samples from lesioned animals suggest that the heteromer is lost following acute or chronic treatment with l-DOPA.

KW - A antagonists

KW - Behavior

KW - CB antagonists

KW - G-protein-coupled receptors

KW - L-DOPA

KW - Parkinson's disease

KW - Radioligand binding

UR - http://www.scopus.com/inward/record.url?scp=84892840403&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84892840403&partnerID=8YFLogxK

U2 - 10.1016/j.expneurol.2013.12.021

DO - 10.1016/j.expneurol.2013.12.021

M3 - Article

C2 - 24412491

AN - SCOPUS:84892840403

VL - 253

SP - 180

EP - 191

JO - Experimental Neurology

JF - Experimental Neurology

SN - 0014-4886

ER -